Janux Therapeutics (JANX) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Janux Therapeutics (JANX) has outperformed MannKind (MNKD) over the past year, losing 21.0% versus a loss of 38.9%. Over five years, JANX leads with a -15.2% price change compared with -32.2% for MNKD. MannKind is the larger company by market cap ($1.10 billion vs $1.08 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JANX | MNKD |
|---|---|---|
| Share price | $17.69 | $3.44 |
| Market cap | $1.08B | $1.10B |
| 1-day change | -1.28% | -0.43% |
| YTD return | +29.86% | -39.15% |
| 1-year return | -21.02% | -38.94% |
| 5-year return | -15.19% | -32.22% |
| Forward P/E | — | 26.94 |
| EPS (TTM) | $-1.64 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $35.34 | $6.51 |
| 52-week low | $12.12 | $2.23 |
| Distance from 52-week high | -49.94% | -47.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +104.86% | +128.24% |
| Average volume | 836.60K | 4.48M |
| Shares outstanding | 61.14M | 321.54M |
| Employees | 113 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JANX has outperformed MNKD by 17.9 percentage points over the past year.
About Janux Therapeutics
JANX stock →Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 113 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
JANX vs MNKD FAQ
Which is bigger, Janux Therapeutics or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.10B compared with $1.08B for Janux Therapeutics (JANX).
Which stock has performed better over the past year, JANX or MNKD?
JANX returned -21.02% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Janux Therapeutics and MannKind in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.